Movement Alert｜ZAI LAB Rises 15.9% in Regular Trading, Q2 Product Revenue Up 11% QoQ with Multiple H2 Catalysts Ahead

Market Focus

Aug 07

On August 7, ZAI LAB rose 15.9% in regular trading, trading at HK$16.84/share, with turnover of HK$330 million.

The surge was driven by the company's Q2 financial results released on the evening of August 6. ZAI LAB reported total revenue of US$106.3 million for Q2, with net product revenue reaching US$105.8 million, representing an 11% sequential increase. The growth was attributed to stable performance of Zejula and continued sales momentum of Efgartigimod. Management indicated multiple pipeline catalysts are expected in the second half of the year.

The strong quarterly results come amid a series of positive developments for the company, including the recent NMPA approval of Tivdak for recurrent or metastatic cervical cancer patients and the European Medicines Agency orphan drug designation for Zoci in neuroendocrine carcinoma of lung origin. These approvals are expected to further expand the company's commercial portfolio and support revenue diversification going forward.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1108413374"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108413374\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108413374?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 13:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108413374","market":"us","top_or_hot":-1,"title":"Movement Alert｜ZAI LAB Rises 15.9% in Regular Trading, Q2 Product Revenue Up 11% QoQ with Multiple H2 Catalysts Ahead","media":"Market Focus","content":"<p><p>On August 7, ZAI LAB rose 15.9% in regular trading, trading at HK$16.84/share, with turnover of HK$330 million.</p><p>The surge was driven by the company's Q2 financial results released on the evening of August 6. ZAI LAB reported total revenue of US$106.3 million for Q2, with net product revenue reaching US$105.8 million, representing an 11% sequential increase. The growth was attributed to stable performance of Zejula and continued sales momentum of Efgartigimod. Management indicated multiple pipeline catalysts are expected in the second half of the year.</p><p>The strong quarterly results come amid a series of positive developments for the company, including the recent NMPA approval of Tivdak for recurrent or metastatic cervical cancer patients and the European Medicines Agency orphan drug designation for Zoci in neuroendocrine carcinoma of lung origin. These approvals are expected to further expand the company's commercial portfolio and support revenue diversification going forward.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ZAI LAB Rises 15.9% in Regular Trading, Q2 Product Revenue Up 11% QoQ with Multiple H2 Catalysts Ahead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ZAI LAB Rises 15.9% in Regular Trading, Q2 Product Revenue Up 11% QoQ with Multiple H2 Catalysts Ahead\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 13:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, ZAI LAB rose 15.9% in regular trading, trading at HK$16.84/share, with turnover of HK$330 million.</p><p>The surge was driven by the company's Q2 financial results released on the evening of August 6. ZAI LAB reported total revenue of US$106.3 million for Q2, with net product revenue reaching US$105.8 million, representing an 11% sequential increase. The growth was attributed to stable performance of Zejula and continued sales momentum of Efgartigimod. Management indicated multiple pipeline catalysts are expected in the second half of the year.</p><p>The strong quarterly results come amid a series of positive developments for the company, including the recent NMPA approval of Tivdak for recurrent or metastatic cervical cancer patients and the European Medicines Agency orphan drug designation for Zoci in neuroendocrine carcinoma of lung origin. These approvals are expected to further expand the company's commercial portfolio and support revenue diversification going forward.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1108413374","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108413374","pubTimestamp":1786081634,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, ZAI LAB rose 15.9% in regular trading, trading at HK$16.84/share, with turnover of HK$330 million.The surge was driven by the company's Q2 financial results released on the evening of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药"},"translate_title":"动态提醒|再鼎医药常规交易上涨15.9%，Q2产品收入环比增长11%，多重H2催化剂即将到来","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"On August 7, ZAI LAB rose 15.9% in regular trading, trading at HK$16.84/share, with turnover of HK$330 million.The surge was driven by the company's Q2 financial results released on the evening of August 6. ZAI LAB reported total revenue of US$106.3 million for Q2, with net product revenue reaching US$105.8 million, representing an 11% sequential increase. The growth was attributed to stable performance of Zejula and continued sales momentum of Efgartigimod. Management indicated multiple pipeline catalysts are expected in the second half of the year.The strong quarterly results come amid a series of positive developments for the company, including the recent NMPA approval of Tivdak for recurrent or metastatic cervical cancer patients and the European Medicines Agency orphan drug designation for Zoci in neuroendocrine carcinoma of lung origin. These approvals are expected to further expand the company's commercial portfolio and support revenue diversification going forward.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}